Jin Rong Jie·2025-08-06 08:43Core Viewpoint - The article highlights the performance of the stock market on August 6, with a focus on the significant price movements of CanSino Biologics, which has a notable A/H share premium and is recognized as a leading high-tech biopharmaceutical company in China [1][3]. Group 1: Market Performance - On August 6, the Shanghai Composite Index rose by 0.45%, closing at 3633.99 points, while the Hang Seng Index increased by 0.03%, closing at 24910.63 points [1]. - CanSino's A-shares closed at 88.48 yuan, reflecting a 6.13% increase, while its H-shares closed at 52.05 HKD, showing a 9.21% rise [1]. Group 2: Company Overview - CanSino Biologics was established in 2009 in China, focusing on providing solutions for the prevention and treatment of infectious diseases globally [1]. - The company specializes in the research, production, and commercialization of innovative, high-quality, and accessible human vaccines, positioning itself as a leading high-tech biopharmaceutical enterprise [1]. - CanSino's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1]. - The company is listed on both the Hong Kong Stock Exchange (H-shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A-shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1].